As Echinocandin antifungal

Indications: Treatment of candidemia and other forms of Candida infections (including those of intra-abdominal, peritoneal, and esophageal locus).

Cautions: Candidal infections: Safety and efficacy have not been established in other Candida infections (eg, endocarditis, osteomyelitis, meningitis.

Contra-indications: Hypersensitivity to anidulafungin, other echinocandins, or any component of the formulation.

Renal Impairment: No dosage adjustment necessary, including dialysis patients.

Hepatic Impairment No dosage adjustment necessary

Side Effects:

Most common:

Cardiovascular: Hypotension hypertension, peripheral edema. Central nervous system: Fever, insomnia. Endocrine & metabolic: Hypokalemia, hypomagnesemia.

Gastrointestinal: Nausea, diarrhea, vomiting. Genitourinary: Urinary tract infection. Hepatic: Alkaline phosphatase increased. Respiratory: Dyspnea.

Miscellaneous: Bacteremia.

Less common:

Cardiovascular: Deep vein thrombosis, chest pain. Central nervous system: Confusion, headache, depression. Dermatologic: Decubitus ulcer. Endocrine & metabolic: Hypoglycemia, dehydration, hyperglycemia, hyperkalemia. Gastrointestinal: Constipation, dyspepsia, abdominal pain, oral candidiasis. Hematologic: Anemia, thrombocythemia, leukocytosis. Hepatic: Transaminases increased. Neuromuscular & skeletal: Back pain. Renal: Creatinine increased. Respiratory: Pleural effusion, cough, pneumonia, respiratory distress. Miscellaneous: Sepsis. Rare: (Limited to important or life-threatening): Amylase increased, anaphylactic shock, anaphylaxis, angioedema, atrial fibrillation, bundle branch block (right), cholestasis, clostridial infection, coagulopathy, ECG abnormality (including QT prolongation), hepatic dysfunction, hepatic necrosis, hepatitis, infusion-related reaction, prothrombin time prolonged, seizure, sinus arrhythmia, thrombocytopenia, thrombophlebitis, ventricular extrasystoles, vision blurred.

Dose: Adult and Geriatric: venous route: Candidemia, intra-abdominal or peritoneal candidiasis: Intravenous route: Initial dose: 200 mg on day 1 subsequent dosing: 100 mg daily treatment should continue until 14 days after last positive culture. Esophageal candidiasis: Initial dose: 100 mg on day 1. subsequent dosing: 50 mg daily. treatment should continue for a minimum of 14 days and for at least 7 days after symptom resolution.

Note: Pediatric dose: Safety and efficacy not established limited data suggest off-label dose of 3 mg/m²/dose IV loading dose, then 1.5 mg/m²/dose IV once daily.